Document:

3-17-15

PROPOPSED INVESTMENT TERM SHEET

 

between

 

EVENT CARDIO GROUP, INC.

 

and

 

(R.J. Capital Management, Ltd.)

 

This term sheet (“Term Sheet”)
between Event Cardio Group Inc. (“ECGI”), a Nevada Corporation with its principle place of business at 2798 Thamesgate
Dr., Mississauga, Ontario, Canada L4T 4E8, and (R. J. Capital Management, Ltd.), a Hong Kong corporation with an address at ____________,
Hong Kong, sets forth the understanding of the parties regarding R. J. Capital Management, Ltd.’s proposed purchase of securities
issued by ECGI. Immediately following the execution of this Term Sheet, the parties shall undertake to formalize this Term Sheet
in a Securities Purchase Agreement.

 

This term sheet is non-binding and subject
to the parties entering into formal agreements setting forth their respective rights and obligations. Such agreements shall contain
customary representations, warranties and indemnifications.

 

Confidentiality

 

The existence of this Term Sheet, all of its
individual terms and conditions and the purchase or issuance contemplated hereby are of a confidential nature and shall not be
disclosed by ECGI to anyone, except its management, board members, advisors, legal counsel and auditors, without the written consent
of R. J. Capital Management, Ltd .

 

 

	Preliminary Terms

         

	Issuer:	Event Cardio Group Inc. (OTC: ECGI)

         

	Investor:	R. J. Capital Management, Ltd. or
        its affiliate

         

	Securities Offered:	Common Stock

         

	Transaction Amount:	US$4 million

         

	Valuation:	Post-money US$20 million on a fully
        diluted basis. There are currently 92 million shares outstanding and 5,000,000 shares issuable upon exercise of outstanding
        options, warrants and convertible debt. Investor will own 24,250,000 shares representing approximately 20% of ECGI’s
        outstanding common stock. If shares or options or other rights exercisable for or convertible into shares of ECGI are
        issued prior to closing, the number of shares to be issued to Investor will be adjusted so as to equal 20% of ECGI’s
        outstanding common stock post-deal.

         

	Structure:	Investor invests $4 million into the public company at closing.

                                                           

	

    	 	 	 

    	 

    
	

        Joint Venture:

         

         

         

         

         
	

        ECGI and the Investor will form
a Joint Venture which will have exclusive distribution and manufacture rights to the BreastCare DTSTM in China. The
initial capitalization of the JV will be $5 million of which $4 million will be contributed by the Investor and $1 million will
be contributed by ECGI. Initially, the ownership of the JV will be Investor – 80%; ECGI – 20%. Investor will have
the right to invest an additional $5 million prior to dilution of ECGI’s 20%..

         

	Use of Proceeds:	ECGI will use the proceeds to commercialize
        the BreastCare DTSTM device in North America and the People’s Republic of China

         

	Governing Law:	New York Law

         

	Others:	The parties acjnowledge that the execution         of the Securities
    Purchase Agreement is subject to R. J. Capital Management, Ltd’s due diligence to its satisfaction.

                                                           

	Timing;
	

        This offer will remain open
only until 5 PM, March 15, 2015 (Hong Kong Time), and may not be accepted after that date. If accepted, the transaction contemplated
hereby must closing no later than April 1, 2015, subject to the right of R. J. Capital Management, Ltd to extend the closing for
up to 15 days by the payment of $1,000,000 of the $4,000,000 subscription amount. Upon payment of such $1,000,000, ECGI shall
issue to the investor shares representing 5% of the then outstanding shares of ECGI on a fully diluted basis.

 

This term sheet does not constitute or evidence a binding offer
or agreement, nor shall it or any discussions or course of conduct impose any obligation or liability on any of the Parties until
copies have been executed and delivered by both parties. A binding agreement with respect to the proposed transaction will arise
only after the Investor has completed its due diligence (with results satisfactory to them) and mutually satisfactory definitive
agreements have been negotiated and executed (it being understood that the Parties shall not have any obligation or commitment
to enter into such definitive agreements).

 

IN WITNESS WHEREOF, the parties hereto have executed this agreement
as of the date first stated above.

 

 

	Event Cardio Group Inc.

         

         

         

        By: ___/s/ John Bentivoglio_______________

        Name: John Bentivoglio

        Title: President

         

        Agreed and accepted as of the 17th March, 2015
	R. J. Capital Management, Ltd 

         

         

         

        By: ___/s/ Songge Teng_______________

        Name: Songge Teng

        Title: Director

         

        Agreed and accepted as of 17th March 2015Exhibit 10.1

 

EMPLOYMENT AGREEMENT

 

This EMPLOYMENT AGREEMENT
(the “Agreement”) between Synthetic Biologics, Inc. (formerly known as Adeona Pharmaceuticals, Inc.),
a Nevada corporation, (the “Company”), and Jeffrey Riley (the “Executive”)
is effective as of March 18, 2015 (the “Effective Date”).

 

WITNESSETH:

 

WHEREAS, the
Executive has been employed by the Company as its President and Chief Executive Officer pursuant to the terms of an Employment
Agreement dated February 3, 2012 (the “Prior Employment Agreement”); 

 

WHEREAS, the
Company desires to continue to employ the Executive as its President and Chief Executive Officer and the Executive desires to accept
such employment, on the terms and conditions set forth in this Agreement; and

 

WHEREAS, the
Company and the Executive have mutually agreed that, as of the Effective Date, this Agreement shall replace the Prior Employment
Agreement in its entirety.

 

NOW, THEREFORE,
in consideration of the promises and the mutual covenants and agreements contained herein and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as
follows:

 

1.                 
EMPLOYMENT.

 

(a)               
TERMINATION OF PRIOR EMPLOYMENT AGREEMENT. Effective as of 11:59 p.m. on the day immediately prior to the Effective
Date, the Prior Employment Agreement shall automatically terminate and be of no further force and effect.

 

(b)              
EMPLOYMENT TERM. The Company hereby offers to continue to employ the Executive, and the Executive hereby accepts
continued employment by the Company, upon the terms and conditions set forth in this Agreement, until the termination of the Executive’s
employment in accordance with Section 10 below, as applicable (the “Employment Term”). The Executive
shall be employed for two years unless there is an earlier termination in accordance with Section 10 below.

 

2.                 
POSITION & DUTIES. During the Employment Term, the Executive shall serve as the Company’s President
and Chief Executive Officer. As President and Chief Executive Officer, the Executive shall have such duties, authorities and responsibilities
commensurate with the duties, authorities and responsibilities of persons in similar capacities in similarly sized companies and
such other duties and responsibilities as the Company’s Board of Directors (the “Board”) shall
designate that are consistent with the Executive’s position as President and Chief Executive Officer, including directing,
supervising and having responsibility for all aspects of the operations and general affairs of the Company as directed by the Board.
The Executive shall report to, and be subject to, the lawful direction of the Board. During the Employment Term, the Executive
shall use his best efforts to perform faithfully and efficiently the duties and responsibilities assigned to the Executive hereunder
and devote all of the Executive’s business time (excluding periods of vacation and other approved leaves of absence) to the
performance of the Executive’s duties with the Company. During the Term, the Executive shall also serve, without additional
compensation, as a member of the Board and in such other executive-level positions or capacities as may, from time to time, be
reasonably requested by the Board.

 

    	1

    	 

    

 

3.                 
LOCATION. Unless the parties otherwise agree in writing, at all times during the Employment Term, the Executive’s
principal place of business for performance of the services under this Agreement shall be from various locations.

 

4.                 
BASE SALARY. The Company agrees to pay the Executive a base salary (the “Base Salary”)
at an annual rate of $385,000, payable semi-monthly in accordance with the regular payroll practices of the Company. The Executive’s
Base Salary shall be subject to review and adjustment from time to time by the Board (or a committee thereof) in its sole discretion,
but may not be decreased. The base salary as determined herein from time to time shall constitute “Base Salary” for
purposes of this Agreement.

 

5.                 
ANNUAL BONUS. With respect to each calendar year during the Employment Term (beginning in the year of the
Effective Date), the Executive will be eligible to earn an annual performance bonus (the “Annual Bonus”).
Beginning in the 2015 calendar year and for each full calendar year thereafter, the Executive will be eligible for an Annual Bonus
of up to seventy five percent (75%) of the Base Salary. The Annual Bonus will be based upon the Board’s assessment of the
Executive’s performance and the Company’s attainment of targeted goals as set by the Board in its sole discretion.
The Annual Bonus, if any, will be subject to applicable payroll deductions and withholdings. Following the close of each calendar
year, the Board will determine whether the Executive has earned the Annual Bonus, and the amount of any Annual Bonus, based on
the set criteria. No amount of the Annual Bonus is guaranteed, and the Executive must be an employee in good standing through the
end of the applicable calendar year to be eligible to receive an Annual Bonus; no partial or prorated bonuses will be provided.
The Annual Bonus, if earned, will be paid on or about December 1, but no later than December 31, of the applicable calendar year
for which the Annual Bonus is being measured. The Executive’s eligibility for an Annual Bonus is subject to change in the
discretion of the Board (or any authorized committee thereof).

 

6.                 
EQUITY. In accordance with the terms of the Employment Agreement dated February 3, 2012 between the Executive
and the Company, the Executive was granted a non-qualified option to purchase 750,000 shares of the Company’s publicly traded
common stock (the “Initial Grant”) subject to the terms of the Company’s 2010 Stock Incentive Plan
(as amended) (the “Plan”) and the related stock option agreement between the parties (the “Initial
Grant Agreement”). Except as specifically provided herein, the provisions of the Initial Grant Agreement and the
Executive’s rights with respect to the Initial Grant shall continue.

 

7.                 
EMPLOYEE BENEFITS.

 

(a)              
BENEFIT PLANS. The Executive shall, in accordance with Company policy and the terms of the applicable Company benefit
plan documents, be eligible to participate in any benefit plan or arrangement, including health, life and disability insurance,
retirement plans and the like, that may be in effect from time to time and made available to the Company’s senior management.
All matters of eligibility for coverage or benefits under any benefit plan shall be determined in accordance with the provisions
of such plan. The Company reserves the right to change, alter, or terminate any benefit plan in its sole discretion. Notwithstanding
the foregoing, in the event that the terms of this Agreement differ from or are in conflict with the Company’s general employment
policies or practices, this Agreement shall control.

 

    	2

    	 

    

 

(b)              
VACATION. The Executive shall be entitled to twenty two (22) days paid vacation and sick leave per year in accordance
with the Company’s policies and shall be entitled to accrue ten (10) days of vacation time during the Employment Term in
accordance with the Company’s vacation policy. Vacation is to be taken at such intervals as shall be appropriate and consistent
with the proper performance of the Executive’s duties hereunder. The existing vacation accrued for the past three (3) years
to date not to exceed ten (10) days will rollover into this Agreement.

 

(c)               
SUPPLEMENTAL DISABILITY BENEFITS. During the Employment Term, the Company will pay for the applicable premiums for
the Executive’s coverage under its existing supplemental disability policy.

 

(d)              
GENERAL EXPENSE REIMBURSEMENTS. The Company will reimburse the Executive for all reasonable business expenses, including
travel, computer and cellular phone costs that the Executive incurs in performing the services hereunder pursuant to the Company’s
usual expense reimbursement policies and practices, following submission by the Executive of reasonable documentation thereof.
All reimbursements provided under this Agreement shall be made in accordance with the requirements of Section 409A (as defined
below) to the extent that such reimbursements are subject to Section 409A, including, as applicable, the requirements that (i)
any reimbursement is for expenses incurred during the Employment Term, (ii) the amount of expenses eligible for reimbursement during
a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an
eligible expense shall be made on or before the last day of the calendar year following the calendar year in which the expense
was incurred, and (iv) the right to reimbursement is not subject to liquidation or exchange for any other benefit.

 

(e)               
INDEMNIFICATION. The Company shall provide the Executive will full advance indemnification to the extent permitted
by Nevada law, including indemnification for activities at all subsidiaries.

 

8.                 
CONFIDENTIALITY AND POST-EMPLOYMENT OBLIGATIONS. As a condition of employment, the Executive agrees to execute
and abide by the Company’s current form of Proprietary Information, Inventions, Non-Solicitation and Non-Competition Agreement
(the “Confidentiality Agreement”), which may be amended by the parties from time to time without regard
to this Agreement. The Confidentiality Agreement contains provisions that are intended by the parties to survive and do survive
termination of this Agreement.

 

    	3

    	 

    

 

9.                 
OUTSIDE ACTIVITIES DURING EMPLOYMENT.

 

(a)               
NO ADVERSE INTERESTS. The Executive agrees not to acquire, assume or participate in, directly or indirectly, any
position, investment or interest known by him to be adverse or antagonistic to the Company, its business or prospects, financial
or otherwise during the Employment Term without the consent of the Board. Except with the prior written consent of the Board, during
the Employment Term the Executive will not undertake or engage in any other employment, occupation or business enterprise. Notwithstanding
the foregoing, nothing shall not prevent the Executive from participating in charitable, civic, educational, professional, community
or industry affairs or, with prior approval of the Board, serving on the board of directors or advisory boards of other companies;
provided that such activities or services do not (i) create a conflict with his employment hereunder; (ii) materially interfere
with the performance of his duties; or (iii) violate the terms of the Confidentiality Agreement.

 

(b)              
NONCOMPETITION. Other than as permitted by Section 9(a), during the Employment Term and for the one year period thereafter
(the “Non-Competition Period”), except on behalf of the Company, the Executive will not directly or indirectly, whether
as an officer, director, stockholder, partner, proprietor, associate, representative, consultant, or in any capacity whatsoever
engage in, become financially interested in, participate in, be employed by or have any business connection with any other person,
corporation, firm, partnership or other entity whatsoever which competes with the Company, anywhere throughout the world, in any
line of business engaged in (or planned to be engaged in) by the Company other than de minimis stock holdings in public companies;
provided, however, that anything above to the contrary notwithstanding, he may own, as a passive investor, securities of
any competitor corporation, so long as his direct holdings in any one such corporation shall not in the aggregate constitute more
than one percent (1%) of the voting stock of such corporation, and provided that the Executive promptly discloses to the
Board any such participation, other than such de minimis stock holdings. 

 

(c)               
NONSOLICITATION. During the Non-Competition Period, Executive shall not, directly or
indirectly, (i) induce or attempt to induce or aid others in inducing anyone working at or for the Company to cease working at
or for the Company, or in any way interfere with the relationship between the Company and anyone working at or for the Company
except in the proper exercise of Executive’s authority or (ii) in any way interfere with the relationship between the Company
and any customer, supplier, licensee or other business relation of the Company.

 

(d) SCOPE.  If,
at the time of enforcement of this Section 9, a court shall hold that the duration, scope, area or other restrictions stated herein
are unreasonable under circumstances then existing, the parties agree that the maximum duration, scope, area or other restrictions
reasonable under such circumstances shall be substituted for the stated duration, scope, area or other restrictions.

 

(e) INDEPENDENT AGREEMENT.  The
covenants made in this Section 9 shall be construed as an agreement independent of any other provisions of this Agreement, and
shall survive the termination of this Agreement.  Moreover, the existence of any claim or cause of action of Executive
against the Company or any of its affiliates, whether or not predicated upon the terms of this Agreement, shall not constitute
a defense to the enforcement of these covenants.

 

    	4

    	 

    

 

10.             
TERMINATION. The Executive’s employment and the Employment Term shall terminate on the first of the
following to occur:

 

(a)               
DISABILITY. Upon the 30th day following the Executive’s receipt of notice of the Company’s
termination due to Disability (as defined in this Section); provided that, the Executive has not returned to full-time performance
of his duties within thirty (30) days after receipt of such notice. If the Company determines in good faith that the Executive’s
Disability has occurred during the term of this Agreement, it will give the Executive written notice of its intention to terminate
his employment.  For purposes of this Agreement, “Disability” shall occur when the Board determines
that the Executive has become physically or mentally incapable of performing the essential functions of his job duties under this
Agreement with or without reasonable accommodation, for ninety (90) consecutive days or one hundred twenty (120) nonconsecutive
days in any twelve (12) month period. For purposes of this Section, at the Company’s request, the Executive agrees to make
himself available and to cooperate in a reasonable examination by an independent qualified physician selected by the Board.

 

(b)              
DEATH. Automatically on the date of death of the Executive.

 

(c)               
CAUSE. Immediately upon written notice by the Company to the Executive of a termination for Cause. For purposes of
this Agreement, “Cause” shall mean the occurrence of any of the following events, as determined by the
Board in its sole and absolute discretion: (i) gross insubordination, acts of embezzlement or misappropriation of funds, fraud,
dereliction of fiduciary obligations; (ii) conviction of a felony or other crime involving moral turpitude, dishonesty or theft
(including entry of a nolo contendere plea); (iii) willful unauthorized disclosure of confidential information belonging
to the Company or entrusted to the Company by a client; (iv) material violation of any provision of this Agreement, of any Company
policy, and/or of the Confidentiality Agreement, which, to the extent it is curable by the Executive, is not cured by the Executive
within thirty (30) days of receiving written notice of such violation by the Company; (v) being under the influence of drugs (other
than prescription medicine or other medically-related drugs to the extent that they are taken in accordance with their directions)
during the performance of the Executive’s duties under this Agreement; (vi) engaging in behavior that would constitute grounds
for liability for harassment (as proscribed by the U.S. Equal Employment Opportunity Commission Guidelines or any other applicable
state or local regulatory body) or other egregious conduct that violates laws governing the workplace; (vii) willful failure to
perform his written assigned tasks, where such failure is attributable to the fault of the Executive which, to the extent it is
curable by the Executive, is not cured by Executive within thirty (30) days of receiving written notice of such violation by the
Company.

 

(d)              
WITHOUT CAUSE. Upon written notice by the Company to the Executive of an involuntary termination without Cause and
other than due to death or Disability.

 

(e)               
WITH GOOD REASON. Upon the Executive’s notice following the end of the Cure Period (as defined in this Section).
For purposes of this Agreement, “Good Reason” for the Executive to terminate his employment hereunder
shall mean the occurrence of any of the following events without the Executive’s consent: (i) a material reduction in the
Executive’s Base Salary (other than an across-the-board decrease in base salary applicable to all executive officers of the
Company); (ii) a material breach of this Agreement by the Company; (iii) a material reduction in the Executive’s duties,
authority and responsibilities relative to the Executive’s duties, authority, and responsibilities in effect immediately
prior to such reduction; or (iv) the relocation of the Executive’s principal place of employment, without the Executive’s
consent, in a manner that lengthens his one-way commute distance by fifty (50) or more miles from his then-current principal place
of employment immediately prior to such relocation; provided, however, that, any such termination by the Executive shall
only be deemed for Good Reason pursuant to this definition if: (1) the Executive gives the Company written notice of his intent
to terminate for Good Reason within thirty (30) days following the first occurrence of the condition(s) that he believes constitute(s)
Good Reason, which notice shall describe such condition(s); (2) the Company fails to remedy such condition(s) within thirty (30)
days following receipt of the written notice (the “Cure Period”); and (3) the Executive voluntarily terminates
his employment within thirty (30) days following the end of the Cure Period.

 

    	5

    	 

    

 

(f)               
WITHOUT GOOD REASON. Upon the expiration of the Transition Period (as defined in this Section) unless otherwise provided
by the Company as provided herein. The Executive shall provide thirty (30) days’ prior written notice (the “Transition
Period”) to the Company of the Executive’s intended termination of employment without Good Reason (“Voluntary
Termination”). During the Transition Period, the Executive shall assist and advise the Company in any transition
of business, customers, prospects, projects and strategic planning, and the Company shall continue to pay Executive’s Base
Salary and benefits through the end of the Transition Period. The Company may, in its sole discretion, upon five (5) days prior
written notice to the Executive, make such termination of employment effective earlier than the expiration of the Transition Period
(“Early Termination Right”), but it shall pay the Executive’s Base Salary and benefits through
the earlier of: the end of the Transition Period, or the date that the Executive accepts full-time employment or a full-time consulting
engagement from a third party.

 

11.             
CONSEQUENCES OF TERMINATION. Any termination payments made and benefits provided under this Agreement to
the Executive shall be in lieu of any termination or severance payments or benefits for which the Executive may be eligible under
any of the plans, policies or programs of the Company or its affiliates as may be in effect from time to time. Subject to satisfaction
of each of the conditions set forth in Section 12, the following amounts and benefits shall be due to the Executive. Any Accrued
Amounts (as defined in Section 11(a)) shall be payable on the next regularly scheduled Company payroll date following the date
of termination or earlier if required by applicable law.

 

(a)               
DISABILITY. Upon employment termination due to Disability, the Company shall pay or provide the Executive: (i) any
unpaid Base Salary through the date of termination and any accrued vacation; (ii) any unpaid Annual Bonus earned with respect to
any calendar year ending on or preceding the date of termination; (iii) reimbursement for any unreimbursed expenses incurred through
the date of termination; and (iv) all other payments and benefits to which the Executive may be entitled under the terms of any
applicable compensation arrangement or benefit, equity or perquisite plan or program or grant or this Agreement, including but
not limited to any applicable insurance benefits (collectively, “Accrued Amounts”). In addition, upon
the Executive’s termination due to Disability, the Executive shall be entitled to exercise any vested equity award(s) granted
to the Executive for a period equal to the shorter of: (i) six (6) months after termination, or (ii) the remaining term of the
award(s).

 

    	6

    	 

    

 

(b)              
DEATH. In the event the Employment Term ends on account of the Executive’s death, the Executive’s estate
(or to the extent a beneficiary has been designated in accordance with a program, the beneficiary under such program) shall be
entitled to any Accrued Amounts, including but not limited to proceeds from any Company sponsored life insurance programs. In addition,
upon the Executive’s death, the Company will extend the time period that the Executive’s estate (or to the extent a
beneficiary has been designated in accordance with a program, the beneficiary under such program) shall be entitled to exercise
any vested equity award(s) granted to the Executive for a period equal to the shorter of: (i) six (6) months after termination,
or (ii) the remaining term of the award(s).

 

(c)               
TERMINATION FOR CAUSE OR WITHOUT GOOD REASON. If the Executive’s employment should be terminated (i) by the
Company for Cause, or (ii) by the Executive without Good Reason, the Company shall pay to the Executive any Accrued Amounts only,
and shall not be obligated to make any additional payments to the Executive.

 

(d)              
TERMINATION WITHOUT CAUSE OR FOR GOOD REASON. If the Executive’s employment by the Company is terminated by
the Company without Cause (and not due to Disability or death) or by the Executive for Good Reason, then the Company shall pay
or provide the Executive with the Accrued Amounts and subject to compliance with Section 12:

 

                                                                   
i.                       
continue payment of the Executive’s Base Salary as in effect immediately preceding the last day of the Employment
Term (ignoring any decrease in Base Salary that forms the basis for Good Reason), for a period of twelve (12) months following
the termination date (the “Severance Period”) on the Company’s regular payroll dates; provided,
however, that any payments otherwise scheduled to be made prior to the effective date of the General Release (namely, the date
it can no longer be revoked) shall accrue and be paid in the first payroll date that follows such effective date with subsequent
payments occurring on each subsequent Company payroll date;

 

                                                                 
ii.                       
if the Executive timely elects continued coverage under COBRA for himself and his covered dependents under the Company’s
group health plans following such termination, then the Company shall pay the COBRA premiums necessary to continue the Executive’s
and his covered dependents’ health insurance coverage in effect for himself (and his covered dependents) on the termination
date until the earliest of (i) twelve (12) months following the termination date; (ii) the date when the Executive becomes eligible
for substantially equivalent health insurance coverage in connection with new employment or self-employment; or (iii) the date
the Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination (such period from
the termination date through the earlier of (i)-(iii), the “COBRA Payment Period”). Notwithstanding the
foregoing, if at any time the Company determines that its payment of COBRA premiums on the Executive’s behalf would result
in a violation of applicable law (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended
by the 2010 Health Care and Education Reconciliation Act), then in lieu of paying COBRA premiums pursuant to this Section, the
Company shall pay the Executive on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment
equal to the COBRA premium for such month, subject to applicable tax withholding (such amount, the “Special Severance
Payment”), such Special Severance Payment to be made without regard to the Executive’s payment of COBRA premiums
and without regard to the expiration of the COBRA period prior to the end of the COBRA Payment Period. Nothing in this Agreement
shall deprive the Executive of his rights under COBRA or ERISA for benefits under plans and policies arising under his employment
by the Company; and

 

    	7

    	 

    

 

                                                               
iii.                       
 Executive shall be entitled to exercise any vested equity award(s) granted to the Executive for a period equal to the shorter
of: (i) six (6) months after termination, or (ii) the remaining term of the award(s).

 

If the Executive’s
employment by the Company is terminated by the Company without Cause (and not due to Disability or death) or by the Executive for
Good Reason, then the Executive will be eligible to receive additional severance benefits including, but not limited to, a pro-rata
portion of the Executive’s Annual Bonus, as determined by the Board of Directors, for the performance year in which the Executive’s
termination occur.

 

12.             
CONDITIONS. Any payments or benefits made or provided pursuant to Section 11 (other than Accrued Amounts)
are subject to the Executive’s (or, in the event of the Executive’s death, the beneficiary’s or estate’s,
or in the event of the Executive’s Disability, the guardian’s):

 

(a)               
compliance with the provisions of Section 8 hereof;

 

(b)              
delivery to the Company of an executed waiver and general release of any and all known and unknown claims, and other provisions
and covenants, in the form acceptable to the Company (which shall be delivered to the Executive within five (5) business days following
the termination date) (the “General Release”) within 21 days of presentation thereof by the Company to
the Executive (or a longer period of time if required by law), and permitting the General Release to become effective in accordance
with its terms; and

 

(c)               
delivery to the Company of a resignation from all offices, directorships and fiduciary positions with the Company, its affiliates
and employee benefit plans effective as of the termination date.

 

Notwithstanding the
due date of any post-employment payments, any amounts due following a termination under this Agreement (other than Accrued Amounts)
shall not be due until after the expiration of any revocation period applicable to the General Release without the Executive having
revoked such General Release, and any such amounts shall be paid or commence being paid to the Executive within fifteen (15) days
of the expiration of such revocation period without the occurrence of a revocation by the Executive (or such later date as may
be required under Section 19 of this Agreement). Nevertheless (and regardless of whether the General Release has been executed
by the Executive), upon any termination of the Executive’s employment, the Executive shall be entitled to receive any Accrued
Amounts, payable after the date of termination in accordance with the Company’s applicable plan, program, policy or payroll
procedures. Notwithstanding anything to the contrary in this Agreement, if any severance pay or benefits are deferred compensation
under Section 409A (as defined below), and the period during which the Executive may sign the General Release begins in one calendar
year and the first payroll date following the period during which the Executive may sign the General Release occurs in the following
calendar year, then the severance pay or benefit shall not be paid or the first payment shall not occur until the later calendar
year.

 

    	8

    	 

    

 

13.             
CONSEQUENCES OF A CHANGE IN CONTROL.

 

(a)               
Upon the closing of a Change in Control (as defined below), the time period that the Executive shall have to exercise all
vested stock options and other awards that the Executive may have under the Plan (including the Initial Grant) or any successor
equity compensation plan as may be in place from time to time shall be equal to the shorter of: (i) six (6) months days after termination,
or (ii) the remaining term of the award(s).

 

(b)              
If within one year after the occurrence of a Change in Control, the Executive terminates his employment with the Company
for Good Reason or the Company terminates the Executive's employment for any reason other than death, Disability or Cause, the
Company (or the then former Company subsidiary employing the Executive), or the consolidated, surviving or transferee person in
the event of a Change in Control pursuant to a consolidation, merger or sale of assets, the Executive shall be entitled to receive
from the Company (i) the portion of the Base Salary for periods prior to the effective date of termination accrued but unpaid (if
any); (ii) all unreimbursed expenses (if any), subject to Section 7(b); (iii) an aggregate amount (the “Change in Control
Severance Amount”) equal to two times the sum of the Base Salary plus an amount equal to the bonus that would be payable
if the “target” level performance were achieved under the Company's annual bonus plan (if any) in respect of the fiscal
year during which the termination occurs (or the prior fiscal year if bonus levels have not yet been established for the year of
termination); and (iv) the payment or provision of any Other Benefits. The Change in Control Severance Amount shall be paid in
a lump sum, if the Change in Control event constitutes a “change in the ownership” or a “change in the effective
control” of the Company or a “change in the ownership of a substantial portion of a corporation's assets” (each
within the meaning of Section 409A), or in 48 substantially equal payments, if the Change in Control event does not so comply with
Section 409A. The lump sum amount shall be paid, or the installment payments shall commence, as applicable, on the first scheduled
payroll date (in accordance with the Company's payroll schedule in effect for the Executive immediately prior to such termination)
that occurs on or following the date that is 30 days after the Executive's termination of employment; provided, however,
that the payment of such severance amount is subject to the Executive's compliance with the requirement to deliver the General
Release contemplated pursuant to Section 12(b). Any such installment payment shall be treated as a separate payment as defined
under Treasury Regulation §1.409A-2 (b)(2). If the Executive is a “specified employee” (as determined under the
Company's policy for identifying specified employees) on the date of his “separation from service” (within the meaning
of Section 409A) and if any portion of the severance amount described in clause (iii) would be considered “deferred compensation”
under Section 409A, such severance amount shall not be paid or commence to be paid on any date prior to the first business day
after the date that is six months following the Executive's separation from service (unless any such payment(s) shall satisfy the
short-term deferral rule, as defined in Treasury Regulation §1.409A-1(b)(4), or shall be treated as separation pay under Treasury
Regulation §1.409A-1(b)(9)(iii) or §1.409A-1(b)(9)(v)). If paid in installments, the first payment that can be made shall
include the cumulative amount of any amounts that could not be paid during such six-month period. In addition, interest will accrue
at the 10-year T-bill rate (as in effect as of the first business day of the calendar year in which the separation from service
occurs) on such lump sum amount or installment payments, as applicable, not paid to the Executive prior to the first business day
after the sixth month anniversary of his separation from service that otherwise would have been paid during such six-month period
had this delay provision not applied to the Executive and shall be paid at the same time at which the lump sum payment or the first
installment payment, as applicable, is made after such six-month period. Notwithstanding the foregoing, a payment delayed pursuant
to the preceding three sentences shall commence earlier in the event of the Executive's death prior to the end of the six-month
period. Upon the termination of employment with the Company for Good Reason by the Executive or upon the involuntary termination
of employment with the Company of the Executive for any reason other than death, Disability or Cause, in either case within two
years after the occurrence of a Change in Control, the Company (or the then former Company subsidiary employing the Executive),
or the consolidated, surviving or transferee person in the event of a Change in Control pursuant to a consolidation, merger or
sale of assets, shall also provide, for the period of two consecutive years commencing on the date of such termination of employment,
medical, dental, life and disability insurance coverage for the Executive and the members of his family which is not less favorable
to the Executive than the group medical, dental, life and disability insurance coverage carried by the Company for the Executive
and the members of his family at the time of termination.

 

    	9

    	 

    

 

(c) For purposes of this Agreement,
“Change in Control” means:

 

(i) any person or entity becoming the beneficial
owner, directly or indirectly, of securities of the Company representing fifty percent (50%) of the total voting power of all its
then outstanding voting securities;

 

(ii) a merger or consolidation of the Company
in which its voting securities immediately prior to the merger or consolidation do not represent, or are not converted into securities
that represent, a majority of the voting power of all voting securities of the surviving entity immediately after the merger or
consolidation; or

 

(iii) a sale of substantially
all of the assets of the Company or a liquidation or dissolution of the Company.

 

14.             
ASSIGNMENT. This Agreement shall be binding upon and inure to the benefit of the Executive and the Executive’s
heirs, executors, personal representatives, assigns, administrators and legal representatives. Because of the unique and personal
nature of the Executive’s duties under this Agreement, neither this Agreement nor any rights or obligations under this Agreement
shall be assignable by the Executive. This Agreement shall be binding upon and inure to the benefit of the Company and its successors,
assigns and legal representatives. Any such successor or assign of the Company will be deemed substituted for the Company under
the terms of this Agreement for all purposes. For this purpose, “successor” means any person, firm, corporation or
other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially
all of the assets or business of the Company.

 

    	10

    	 

    

 

15.             
NOTICE. For the purpose of this Agreement, notices and all other communications provided for in this Agreement
shall be in writing and shall be deemed to have been duly given (a) on the date of delivery if delivered by hand, (b) on the date
of transmission, if delivered by confirmed facsimile, (c) on the first business day following the date of deposit if delivered
by guaranteed overnight delivery service, or (d) on the fourth business day following the date delivered or mailed by United States
registered or certified mail, return receipt requested, postage prepaid, addressed as follows:

 

If to the
Company:

 

Synthetic
Biologics, Inc.

Attn: Board
of Directors

155 Gibbs
Street, Suite 412

Rockville,
MD 20850

(734) 332-7878
(fax)

 

and a copy
(which shall not constitute notice) shall also be sent to:

 

Leslie Marlow,
Esq.

Gracin &
Marlow, LLP

405 Lexington
Avenue, 26th Floor

New York,
New York 10174

(212) 208-4657

 

If to the
Executive:

 

To the most
recent address of the Executive set forth in the personnel records of the Company.

 

or to such other address
as either party may have furnished to the other in writing in accordance herewith, except that notices of change of address shall
be effective only upon receipt.

 

16.             
SECTION HEADINGS; INCONSISTENCY. The section headings used in this Agreement are included solely for convenience
and shall not affect, or be used in connection with, the interpretation of this Agreement. If there is any inconsistency between
this Agreement and any other agreement (including but not limited to any option, stock, long-term incentive or other equity award
agreement), plan, program, policy or practice (collectively, “Other Provision”) of the Company the terms
of this Agreement shall control over such Other Provision.

 

17.             
SEVERABILITY. The provisions of this Agreement shall be deemed severable and the invalidity of unenforceability
of any provision shall not affect the validity or enforceability of the other provisions hereof.

 

18.             
COUNTERPARTS. This Agreement may be executed in counterparts, each of which shall be deemed to be an original
but all of which together will constitute one and the same instruments. One or more counterparts of this Agreement may be delivered
by facsimile, with the intention that delivery by such means shall have the same effect as delivery of an original counterpart
thereof.

 

    	11

    	 

    

 

19.             
SECTION 409A.

 

(a)               
Notwithstanding anything to the contrary herein, the following provisions apply to the extent severance benefits provided
herein are subject to Section 409A of the Internal Revenue Code (the “Code”) and the regulations and
other guidance thereunder and any state law of similar effect (collectively “Section 409A”). Severance
benefits shall not commence until the Executive has a “separation from service” (as defined under Treasury Regulation
Section 1.409A-1(h), without regard to any alternative definition thereunder, a “separation from service”). Each installment
of severance benefits is a separate “payment” for purposes of Treas. Reg. Section 1.409A-2(b)(2)(i), and the severance
benefits are intended to satisfy the exemptions from application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4)
and 1.409A-1(b)(9). However, if such exemptions are not available and the Executive is, upon separation from service, a “specified
employee” for purposes of Section 409A, then, solely to the extent necessary to avoid adverse personal tax consequences under
Section 409A, the timing of the severance benefits payments shall be delayed until the earlier of (i) six (6) months and one day
after the Executive’s separation from service, or (ii) the Executive’s death. The parties acknowledge that the exemptions
from application of Section 409A to severance benefits are fact specific, and any later amendment of this Agreement to alter the
timing, amount or conditions that will trigger payment of severance benefits may preclude the ability of severance benefits provided
under this Agreement to qualify for an exemption.

 

(b)              
It is intended that this Agreement shall comply with the requirements of Section 409A, and any ambiguity contained herein
shall be interpreted in such manner so as to avoid adverse personal tax consequences under Section 409A. Notwithstanding the foregoing,
the Company shall in no event be obligated to indemnify the Executive for any taxes or interest that may be assessed by the Internal
Revenue Service pursuant to Section 409A of the Code to payments made pursuant to this Agreement.

 

20.             
SECTION 4999 EXCISE TAX.

 

(a)               
If any payments, rights or benefits (whether pursuant to the terms of this Agreement or any other plan, arrangement or agreement
of the Executive with the Company or any person affiliated with the Company) (the “Payments”) received
or to be received by the Executive will be subject to the tax (the “Excise Tax”) imposed by Section 4999
of the Code (or any similar tax that may hereafter be imposed), then, except as set forth in Section 20(b) below, the Company shall
pay to the Executive an amount in addition to the Payments (the “Gross-Up Payment”) as calculated below.
The Gross Up Payment shall be in an amount such that, after deduction of any Excise Tax on the Payments and any federal, state
and local income and employment tax and Excise Tax on the Gross Up Payment, but before deduction for any federal, state or local
income and employment tax on the Payments, the net amount retained by the Executive shall be equal to the Payments.

 

(b)              
The process for calculating the Excise Tax, determining the amount of any Gross-Up Payment and other procedures relating
to this Section 20, including the time period for making the Gross-Up Payment, are set forth in Appendix A attached
hereto. For purposes of making the determinations and calculations required herein, the Accounting Firm (as defined in Appendix
A) may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code,
provided that the Accounting Firm shall make such determinations and calculations on the basis of “substantial authority”
(within the meaning of Section 6662 of the Code) and the Company shall use reasonable efforts to cause the Accounting Firm to provide
opinions to that effect to both the Company and Executive.

 

    	12

    	 

    

 

21.             
REPRESENTATIONS. The Executive represents and warrants to the Company that the Executive has the legal right
to enter into this Agreement and to perform all of the obligations on the Executive’s part to be performed hereunder in accordance
with its terms and that the Executive is not a party to any agreement or understanding, written or oral, which could prevent the
Executive from entering into this Agreement or performing all of the Executive’s obligations hereunder. The Executive further
represents and warrants that he has been advised to consult with an attorney and that he has been represented by the attorney of
his choosing during the negotiation of this Agreement, that he has consulted with his attorney before executing this Agreement,
that he has carefully read and fully understand all of the provisions of this Agreement and that he is voluntarily entering into
this Agreement.

 

22.             
WITHHOLDING. The Company may withhold from any and all amounts payable under this Agreement such federal,
state and local taxes as may be required to be withheld pursuant to any applicable law or regulation.

 

23.             
SURVIVAL. The respective obligations of, and benefits afforded to, the Company and the Executive which by
their express terms or clear intent survive termination of the Executive’s employment with the Company, including, without
limitation, the provisions of Section 8 and Sections 10 through 29, inclusive of this Agreement, will survive termination of the
Executive’s employment with the Company, and will remain in full force and effect according to their terms.

 

24.             
AGREEMENT OF THE PARTIES. The language used in this Agreement will be deemed to be the language chosen by
the parties hereto to express their mutual intent, and no rule of strict construction will be applied against any party hereto.
No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made
by either party which are not expressly set forth in this Agreement. Neither the Executive nor the Company shall be entitled to
any presumption in connection with any determination made hereunder in connection with any arbitration, judicial or administrative
proceeding relating to or arising under this Agreement.

 

25.             
INTEGRATION. This Agreement, together with the Confidentiality Agreement and the Initial Grant Agreement,
contains the complete, final and exclusive agreement of the parties relating to the terms and conditions of the Executive’s
employment and the termination of the Executive’s employment, and supersedes all prior and contemporaneous oral and written
employment agreements or arrangements between the parties, including but not limited to the Prior Employment Agreement. The Executive
acknowledges and agrees that the Company has fully satisfied, and has no further obligations to the Executive arising under, or
relating to, the Prior Employment Agreement or any other employment or consulting arrangement or understanding or otherwise.

 

    	13

    	 

    

 

26.             
AMENDMENT. This Agreement cannot be amended or modified except by a written agreement signed by the Executive
and a duly authorized officer of the Company.

 

27.             
WAIVER. No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except
with the written consent of the party against whom the wavier is claimed, and any waiver or any such term, covenant, condition
or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant, condition
or breach.

 

28.             
CHOICE OF LAW. This Agreement shall be construed and interpreted in accordance with the internal laws of the
State of Delaware without regard to its conflict of laws principles.

 

29.             
DISPUTE RESOLUTION. To ensure the rapid and economical resolution of disputes that may arise in connection
with the Executive’s employment with the Company, the Executive and the Company both agree that any and all disputes, claims,
or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement,
breach, performance, or interpretation of this Agreement, the Executive’s employment with the Company, or the termination
of the Executive’s employment from the Company, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16,
and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted in Delaware by JAMS, Inc.
(“JAMS”) or its successors.  Both the Executive and the Company acknowledge that by agreeing to this
arbitration procedure, each waives the right to resolve any such dispute through a trial by jury or judge or administrative proceeding.
 Any such arbitration proceeding will be governed by JAMS’ then applicable rules and procedures for employment disputes,
which can be found at http://www.jamsadr.com/rules-clauses/, and which
will be provided to the Executive upon request. In any such proceeding, the arbitrator shall: (i) have the authority to compel
adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (ii)
issue a written arbitration decision including the arbitrator’s essential findings and conclusions and a statement of the
award. The Executive and the Company each shall be entitled to all rights and remedies that either would be entitled to pursue
in a court of law; provided, however, that in no event shall the arbitrator be empowered to hear or determine any class
or collective claim of any type. Nothing in this Agreement is intended to prevent either the Company or the Executive from obtaining
injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration pursuant to applicable law.
The Company shall pay all filing fees in excess of those which would be required if the dispute were decided in a court of law,
and shall pay the arbitrator’s fees and any other fees or costs unique to arbitration.

 

    	14

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement, effective as of the date first written above.

 

	 	Synthetic Biologics, Inc.
	 	 	 
	 	By:	/s/ C. Evan Ballantyne 
	 	 	C. Evan Ballantyne
	 	 	Chief Financial Officer
	 	 	 
	 	Date:	3/18/2015
	 	 	 
	 	Jeffrey Riley
	 	 	 
	 	/s/ Jeffrey Riley
	 	Date:	3/18/2015

  

    	15

    	 

    

 

APPENDIX A

 

TAX GROSS-UP PAYMENT
RULES AND PROCEDURES

 

1.                 
Subject to Paragraph 3 below, all determinations required to be made under Section 20 of this Agreement, including whether
a Gross-Up Payment is required and the amount of such Gross-Up Payment, shall be made by an accounting firm (the “Accounting
Firm”) selected in accordance with Paragraph 2 below. The Company shall use reasonable efforts to cause the Accounting
Firm to provide detailed supporting calculations both to the Company and Executive within 15 business days before the event that
results in the potential for an excise tax liability for the Executive, which could include but is not limited to a Change in Control
and the subsequent vesting of any cash payments or awards, or the Executive’s termination of employment, or such earlier
time as is required by the Company. The initial Gross-Up Payment, if any, as determined pursuant to this Paragraph 1, shall be
paid on the Executive’s behalf to the applicable taxing authorities by no later than the date the Executive is required to
remit the taxes to such taxing authority. If the Accounting Firm determines that no Excise Tax is payable to the Executive, the
Company shall use reasonable efforts to cause the Accounting Firm to furnish the Executive with a written report indicating that
he has substantial authority not to report any Excise Tax on his federal income tax return. Any determination by the Accounting
Firm shall be binding upon the Company and Executive. As a result of the uncertainty in the application of Section 4999 of the
Code at the time of the initial determination by the Accounting Firm hereunder, it is possible that Gross-Up Payments which will
not have been made by the Company should have been made (“Underpayment”), consistent with the calculations
required to be made hereunder. In the event that the Company exhausts its remedies pursuant to Paragraph 3 below and the Executive
thereafter is required to make a payment or additional payment of any Excise Tax, the Accounting Firm shall determine the amount
of the Underpayment that has occurred and any such Underpayment, increased by all applicable interest and penalties associated
with the Underpayment, shall be promptly paid by the Company to or for the benefit of the Executive. For purposes of determining
the amount of the Gross-Up Payment, the Executive shall be deemed to pay federal income tax at the highest marginal rate of federal
income taxation in the calendar year in which the Gross-Up Payment is to be made and state and local income taxes on earned income
at the highest marginal rate of taxation in the state and locality of the Executive’s residence on the Effective Date of
Termination, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local
taxes.

 

2.                 
The Accounting Firm shall be a public accounting firm proposed by the Company and agreed upon by the Executive. If the Executive
and the Company cannot agree on the firm to serve as the Accounting Firm within ten (10) days after the date on which the Company
proposed to the Executive a public accounting firm to serve in such capacity, then the Executive and the Company shall each select
one accounting firm and those two firms shall jointly select the accounting firm to serve as the Accounting Firm within ten (10)
days after being requested by the Company and the Executive to make such selection. The Company shall pay the fees of the Accounting
Firm.

 

    	 

    	 

    

 

3.                 
The Executive shall notify the Company in writing of any claim by the Internal Revenue Service that, if successful, would
require the payment by the Company of the Gross-Up Payment. Such notification shall be given as soon as practicable but no later
than fifteen (15) business days after the Executive knows of such claim and shall apprise the Company of the nature of such claim
and the date on which such claim is requested to be paid. The Executive shall not pay such claim prior to the expiration of the
period ending on the date that any payment of taxes with respect to such claim is due or the thirty day period following the date
on which the Executive gives such notice to the Company, whichever period is shorter. If the Company notifies the Executive in
writing prior to the expiration of such period that it desires to contest such claim, the Executive shall (i) give the Company
any information reasonably requested by the Company relating to such claim, (ii) take such action in connection with contesting
such claim as the Company shall reasonably request in writing from time to time, including, without limitation, accepting legal
representation with respect to such claim by an attorney reasonably selected by the Company, (iii) cooperate with the Company in
good faith in order effectively to contest such claim, and (iv) permit the Company to participate in any proceedings relating to
such claim; provided, however, that the Company shall bear and pay directly all costs and expenses (including attorneys’
fees and any additional interest and penalties) incurred in connection with such contest and shall indemnify and hold the Executive
harmless, on an after-tax basis, for any Excise Tax or income tax, including interest and penalties with respect thereto, imposed
as a result of such representation and payment of costs and expenses. Without limitation of the foregoing provisions of this Paragraph
3, the Company shall control all proceedings taken in connection with such contest and, at its sole option, may pursue or forego
any and all administrative appeals, proceedings, hearings and conferences with the taxing authority in respect to such claim and
may, at its sole option, either direct the Executive to pay the tax claimed and sue for a refund or contest the claim in any permissible
manner, and the Executive agrees to prosecute such contest to a determination before any administrative tribunal, in a court of
initial jurisdiction and in one or more appellate courts, as the Company shall determine; provided, however, that if the
Company directs the Executive to pay such claim and sue for a refund, the Company shall advance the amount of such payment to Executive,
on an interest-free basis and shall indemnify and hold the Executive harmless, on an after-tax basis, from any Excise Tax and income
tax, including interest or penalties with respect thereto, imposed with respect to such advance or with respect to any imputed
income with respect to such advance; and further provided that any extension of the statute of limitations relating to payment
of taxes for the taxable year of the Executive with respect to which such contested amount is claimed to be due is limited solely
to such contested amount. Furthermore, the Company’s control of the contest shall be limited to issues with respect to which
a Gross-Up Payment would be payable hereunder and the Executive shall be entitled to settle or contest, as the case may be, any
other issue raised by the Internal Revenue Service or any other authority.

 

4.                 
If, after the receipt by the Executive of an amount advanced by the Company pursuant to Paragraph 3 above, the Executive
becomes entitled to receive any refund with respect to such claim, the Executive shall (subject to the Company’s complying
with the requirements of Paragraph 3), promptly pay to the Company the amount of such refund (together with any interest paid
or credited thereon after taxes applicable thereto).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]